There are over 100 cannabinoids in the cannabis plant, but a handful of them do most of the work. Once you understand how they relate β which ones convert into which, and why β the whole landscape gets much easier to navigate.
Start with the parent compound
Every cannabinoid in cannabis starts as the same molecule: CBGA, cannabigerolic acid. Sometimes called "the mother cannabinoid," CBGA is the precursor that the plant's enzymes convert into nearly every other cannabinoid you've heard of.
The plant produces CBGA in its trichomes β the resin glands on flower buds β and then specialized enzymes act on it. Different enzymes produce different cannabinoids. One enzyme converts CBGA into THCA. A different enzyme converts CBGA into CBDA. A third produces CBCA. The plant's genetics determine which enzymes are most active, which is why different cannabis strains produce different cannabinoid profiles.
What this means in practice: when you see a hemp plant labeled "high-THCA," you're not looking at a plant making different molecules than its CBD-dominant cousin. You're looking at a plant whose enzyme expression favors the THCA pathway over the CBDA pathway. Same starting material, different chemistry downstream.
The acid forms vs. the neutral forms
Here's the single most important concept for understanding cannabis chemistry, and it's the one most consumers don't quite grasp: cannabinoids exist in two forms β acidic and neutral.
In a living, freshly harvested cannabis plant, almost all cannabinoids exist in their acidic form: THCA, CBDA, CBGA, CBCA. These acidic forms are not psychoactive. They have their own biological activities (some interesting research on anti-inflammatory effects, for example) but they don't produce the classic cannabis intoxication.
When you apply heat β through combustion, vaporization, or even prolonged storage at warm temperatures β the acidic cannabinoids undergo a process called decarboxylation. The "A" group (a carboxylic acid molecule, COOH) falls off. What's left is the neutral form: THC, CBD, CBG, CBC. These neutral forms are the ones with the well-known psychoactive and pharmacological effects.
So when someone says "THCA flower gets you high," what they mean is: the flower contains THCA, which converts to Delta-9 THC when heated, and Delta-9 THC is what produces the effects. The legal classification cares about THCA versus THC. Your body cares about Delta-9 THC, regardless of where it came from.
The major branches of the family
With that foundation, here's how the major cannabinoids relate:
The THC branch
CBGA gets converted by THCA synthase into THCA. Heat THCA, and you get Delta-9 THC (Ξ9-THC) β the primary psychoactive compound in traditional cannabis.
From there, things get interesting. Delta-9 THC is chemically unstable in some ways. Over time, exposed to light and oxygen, it can degrade into CBN (cannabinol) β the compound associated with aged or oxidized cannabis. Many people report CBN as more sedating than THC, though research on this is mixed.
Delta-9 THC can also isomerize into Delta-8 THC (Ξ8-THC), a structural variant with similar but generally milder effects. Most commercial Delta-8 is produced by chemical conversion from CBD rather than extracted from the plant directly, because plants produce very little Delta-8 naturally.
The CBD branch
A different enzyme β CBDA synthase β converts CBGA into CBDA. Heated, CBDA becomes CBD (cannabidiol), the major non-psychoactive cannabinoid that's been studied extensively for anxiety, sleep, inflammation, and seizure disorders.
CBD doesn't get you high in the THC sense, but it's pharmacologically active in many other ways. It interacts with serotonin receptors, modulates the endocannabinoid system indirectly, and has documented effects on a range of conditions.
The CBG branch
If the plant's enzymes don't fully convert CBGA, some of it remains as is. Heated, CBGA becomes CBG (cannabigerol). Most cannabis varieties produce only small amounts of CBG, but some specifically bred "CBG strains" produce significant quantities. CBG is non-psychoactive and has growing research interest for its effects on inflammation and some metabolic conditions.
The CBC branch
CBCA synthase converts CBGA into CBCA, which decarboxylates to CBC (cannabichromene). CBC is one of the four most common cannabinoids in the plant but gets very little attention. Early research suggests anti-inflammatory and possible neuroprotective effects.
The minor cannabinoids worth knowing
Beyond the main branches, several other cannabinoids show up in conversations about hemp products. Most of these exist naturally in very small amounts but have become commercially relevant either through specialized cultivation or through chemical conversion from more abundant precursors:
- THCV (tetrahydrocannabivarin) β A structural cousin of THC, produced from a different precursor (CBGVA instead of CBGA). At low doses it appears to block some THC receptors; at high doses it activates them. Research interest is growing for appetite suppression and metabolic effects, leading to its informal nickname "the diet weed cannabinoid."
- CBDV (cannabidivarin) β The CBD analog from the same alternative pathway. Under investigation for neurological conditions including some forms of epilepsy.
- HHC (hexahydrocannabinol) β A hydrogenated form of THC, more stable to oxidation and light degradation. Naturally occurring in trace amounts; commercially produced via hydrogenation of THC or CBD using nickel or palladium catalysts.
- THCP (tetrahydrocannabiphorol) β A newer-discovered cannabinoid with a longer 7-carbon side chain than THC's 5-carbon chain, reportedly binding cannabinoid receptors many times more tightly. Naturally present in very small quantities; effects in humans at typical dosing aren't yet well-characterized.
- CBNA β CBN β Often discussed as a sleep-promoting cannabinoid, CBN is mostly a degradation product of THC rather than something the plant produces directly in significant amounts. Old cannabis is high in CBN partly because the THC has oxidized over time.
The cannabinoid literature is growing fast. Compounds like CBT, CBL, and various other minor cannabinoids are being studied actively. Many of them will probably stay scientific curiosities; some will become commercially relevant as research progresses.
Terpenes: the other half of the equation
The cannabinoid family tree is only one layer of cannabis chemistry. Sitting alongside it β produced in the same trichomes, often by similar genetic pathways β are the terpenes. These are the aromatic compounds responsible for the smell and much of the character of any given strain.
Terpenes aren't unique to cannabis. The same molecules show up across the plant kingdom. Limonene gives citrus its smell. Pinene is what makes pine trees smell like pine trees. Linalool is the calming aromatic in lavender. Myrcene is prominent in mangoes and hops (which is part of why some IPAs smell vaguely like cannabis).
What makes cannabis unusual is that it produces dozens of terpenes simultaneously, in proportions that vary by strain and growing conditions. A "Sour Diesel" smells different from a "Northern Lights" because the dominant terpene blend is different β even if the cannabinoid profile is similar.
Why does this matter for understanding the cannabinoid family tree? Because there's increasing evidence that terpenes meaningfully modulate cannabinoid effects. The same dose of THC paired with a myrcene-dominant terpene profile produces a noticeably different experience than the same dose paired with a limonene-dominant profile. Research is still working out the exact mechanisms, but most cannabis consumers will tell you from experience that different strains "feel" different in ways that pure cannabinoid concentration doesn't explain.
This is the practical case for full-spectrum products and against single-cannabinoid isolates: the experience of cannabis isn't just THC or just CBD. It's a chemical ensemble.
Why this all matters for products
Understanding the family tree helps decode a lot of what you'll see on hemp product labels.
A "full-spectrum" product contains the complete profile of cannabinoids and terpenes from the source plant β usually dominated by one or two main cannabinoids but including trace amounts of dozens of others. The argument for full-spectrum is the entourage effect: the theory that cannabinoids work better together than in isolation, with each minor compound modulating the effects of the major ones.
A "broad-spectrum" product contains most of the cannabinoid profile but has had specific compounds (usually Delta-9 THC) removed. You get something close to full-spectrum without the psychoactive component.
An "isolate" product contains a single cannabinoid in pure form β 99%+ CBD isolate, 99%+ CBG isolate, etc. The effects are cleaner and more predictable but lack any entourage effect contribution.
Understanding which form of which cannabinoid is in a product, and whether the product has been heated/decarboxylated, tells you a lot more about what to expect than the marketing language alone.
What the family tree doesn't tell you
One important caveat: knowing the cannabinoid profile of a product is necessary but not sufficient for predicting effects. Two products with identical THC content can produce noticeably different experiences because of:
- Terpene profile β the aromatic compounds in cannabis that contribute to strain-specific effects
- Minor cannabinoid ratios β even small differences in CBG, CBC, or CBN can shift the overall experience
- Method of consumption β inhalation vs. oral changes onset, intensity, and duration
- Individual variation β body composition, metabolic rate, prior cannabis tolerance, even genetics all affect how cannabinoids land
The cannabinoid family tree is a map, not the territory. But it's a useful map. Once you know that everything starts with CBGA, that acids convert to neutrals when heated, and that the major branches lead to predictable effects, the rest of the landscape becomes navigable.
